Doctoring Part D
Friday, January 16th, 2009Democrats who opposed many elements of the controversial prescription drug benefit from its passage in 2003 finally have the chance to overhaul it. But will they? Part D is now a huge program with hundreds of competing private plans that would be difficult to dismantle, experts say. Rather than replacing the private system with a drug benefit directly from Medicare, reformers are more likely to move bit by bit.
One proposal would let Medicare negotiate prices directly with drugmakers instead of having insurers do so separately. But it’s unclear how to do this. To negotiate effectively, an insurer must be able to refuse to cover a drug if its maker won’t accept the offered price. “I don’t see Medicare being prepared to do that,” Ginsburg says. “If an insurer excludes Lipitor, the beneficiary can choose another plan that covers it. But if Medicare excludes it, then that’s it—it’s not there” for any beneficiary.
Closing the hated doughnut hole—the coverage gap in Part D—would be popular with beneficiaries but is unlikely because it would cost $300 billion over 10 years.
http://bulletin.aarp.org/yourhealth/medicare/
articles/refining_medicare.html